ltx-315

Biologicalexperimental

Clinical trial activity

7 trials · 16 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started Jan 1, 2010 (NCT01058616)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2018

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • ltx-315
  • ltx-315
  • ltx-315

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06651151Phase 2Nov 1, 2024Lytix Biopharma AS, University of Oslo
NCT05188729Phase 2Feb 1, 2022HeartcoR Solutions, Myonex, Q2 solutions, Veristat, Inc., Verrica Pharmaceuticals Inc.
NCT04796194Phase 2Jun 1, 2021Covance, Lytix Biopharma AS, University of Texas at Houston
NCT03725605Phase 2Dec 28, 2018Lytix Biopharma AS, University of Copenhagen
NCT01986426Phase 1Nov 1, 2013ICON, Lytix Biopharma AS, Theradex, University of London
NCT01223209Phase 1Aug 1, 2010Kael-GemVax Co., Ltd., Lytix Biopharma AS
NCT01058616Phase 1Jan 1, 2010Karolinska Institute, Lytix Biopharma AS, Osaka University, University of Oslo
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (16)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Lytix Biopharma ASFor profit6522010
University of OsloAcademic/Hospital2122010
CovanceFor profit1012021
HeartcoR SolutionsFor profit1012022
ICONFor profit1012013
Kael-GemVax Co., Ltd.For profit1012010
Karolinska InstituteAcademic/Hospital1012010
MyonexFor profit1012022
Osaka UniversityAcademic/Hospital1012010
Q2 solutionsFor profit1012022
TheradexFor profit1012013
University of CopenhagenAcademic/Hospital1012018
University of LondonAcademic/Hospital1012013
University of Texas at HoustonAcademic/Hospital1012021
Veristat, Inc.For profit1012022
Verrica Pharmaceuticals Inc.For profit1112022
16 organizations
Page 1 / 1